William Blair Forecasts MaxCyte’s Q1 Earnings (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT) – Investment analysts at William Blair issued their Q1 2025 EPS estimates for shares of MaxCyte in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst M. Larew forecasts that the company will earn ($0.10) per share for the quarter. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.34) EPS.

A number of other research analysts have also issued reports on the stock. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus cut their price target on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday.

MaxCyte Trading Down 3.8 %

NASDAQ:MXCT opened at $3.06 on Friday. The firm has a market cap of $324.23 million, a price-to-earnings ratio of -9.00 and a beta of 1.35. The company’s 50-day moving average is $4.19 and its two-hundred day moving average is $3.98. MaxCyte has a 12-month low of $2.76 and a 12-month high of $5.26.

Institutional Trading of MaxCyte

Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its holdings in MaxCyte by 123.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company’s stock worth $31,000 after purchasing an additional 4,173 shares during the period. Intech Investment Management LLC purchased a new position in MaxCyte in the 3rd quarter worth about $51,000. BNP Paribas Financial Markets purchased a new position in MaxCyte in the 4th quarter worth about $56,000. Prudential Financial Inc. purchased a new position in MaxCyte during the 4th quarter valued at about $65,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in MaxCyte during the 4th quarter valued at about $74,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.